Laboratory Products 63 Autoclave Manufacturer Awarded ACT Green Credentials
A dedicated British autoclave manufacturer is one of the first to get the ACT label attributed to many of its cylindrical chamber research grade laboratory autoclaves. It highlights how these sterilisers stand up to independent testing and evaluation for efficiency of water and energy use. The ACT program has already been adopted by leaders in the life science industry, including Priorclave, who has already begun labelling its products. It gives increased transparency and assist customers in making smart choices about their purchases.
Lee Oakley, Sales Director at Priorclave said: “I am delighted that the ACT labelling confirms what we already knew. In designing and building our laboratory autoclaves we manufacture reliable, robust sterilises, machines that will ultimately give the customer lower overall cost of ownership.”
The latest ACT labels cover many autoclave models in the Priorclave QCS range. These front loading, cylindrical machine are available in a choice of chamber sizes, from 100 to 400 litres, and in a standard configuration or with vacuum. The opportunity to reduce energy in laboratories is enormous. They consume as much as five times more energy than traditional office buildings and can use millions of gallons of water per year. The ACT label informs users on the manufacturing, energy and water use, packaging and end-of-life, making it easier for customers to choose safe, sustainable products. ACT is the premier eco-nutrition for consumables, chemicals and reagents, and equipment.
Recognised by the Association for the Advancement of Sustainability in Higher Education (AASHE), the American Energy Society, and the International Institute for Sustainable Laboratories, My Green Lab’s Certification is considered the global standard for laboratory sustainability best practices.
Commenting, Lee Oakley said: “We are delighted to adopt the ACT program. It increases transparency and assists customers in making smart choices with their purchases. ACT-labelled products are independently audited by Sustainability Made Simple and verified by My Green Lab. The QCS range of autoclaves is not the first Priorclave product range to be recognised and tested by independent test house My Green Labs.
More information online:
ilmt.co/PL/LKA3 53493pr@reply-direct.com
A Small Workstation with Big Ideas
New Platform Speeds Development of Cell and Gene Therapies
Merck has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform. This new platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%, based on Merck’s experience as a contract development and manufacturing organisation.
“Cell and gene therapies offer the potential for curative treatments and are being developed and commercialised in half the time it has taken traditional therapies,” said Angela Myers, head of Gene Editing & Novel Modalities, Life Science, at Merck. “We are committed to accelerating manufacturing of cell and gene therapies with the ultimate goal of getting these lifesaving treatments to patients faster. By increasing dose yields and dramatically reducing process development time, this new platform will help us reach this goal.”
Don Whitley Scientific is proud to launch their smallest anaerobic workstation: the Whitley A20 Workstation. This anaerobic chamber provides excellent conditions for the processing, incubation and examination of samples without exposure to atmospheric oxygen, and is incredibly gas efficient. It can accommodate 240 x 90mm Petri dishes whilst retaining a generous working area. It will actually hold up to 400 plates for emergency anaerobic incubation.
Managing Director, Paul Walton, commented: “The A20 is the perfect first step-up from using anaerobic jars to using a workstation. It has the same precise control of parameters as our larger workstations, ensuring the very best anaerobic conditions are maintained. Users can check their plates as often as they like and perform tasks inside the workstation without risk to samples.”
This workstation is equipped with two oval, multi- functional glove ports that act as mini airlocks, each capable of transferring 10 x 90mm Petri dishes as a user inserts their arms. A side loading letterbox entry system is also available, providing a straightforward way to quickly introduce individual samples into the workstation. The A20 is fitted with a touch screen providing the user with an intuitive interface for easy control and operation of the workstation.
This workstation is the up-to-date replacement for the Whitley DG250 Workstation, which has been extremely popular with customers for many years. This new model provides modern features such as the full colour touchscreen, remote access, data download (for traceability) and the opportunity to have Anaerobic and Catalyst Conditions Monitoring.
Some particular benefits of this workstation include: very compact footprint - takes up very little bench space but has the same precise control of parameters as our larger workstations; low gas consumption - the A20 runs from two gasses (anaerobic mixed gas and nitrogen) for economic running costs; cost comparisons undertaken by DWS show that it is significantly cheaper to operate a Whitley Workstation than it is to use jars.
More information online:
ilmt.co/PL/LKPm 52661pr@reply-direct.com
Using a suspension cell line rather than an adherent-based production, coupled with a chemically defined cell culture media and process with built-in scalability, Merck’s VirusExpress™ Platform meets multiple market needs. In addition to accelerating process development, the suspension culture format allows each batch of virus to be larger yielding more patient doses. Additionally, suspension culture is amenable to true scale- up, while being less labour-intensive. The chemically defined medium eliminates the safety, regulatory and supply chain concerns related to animal- and human-derived materials.
Merck’s VirusExpress™ Platform offers a simplified upstream workflow, making processes easier to manage, adjust and scale. Flexible licensing allows companies to manufacture vectors by using either Merck’s contract manufacturing capabilities, a third-party contract development and manufacturing organisation, or in-house development.
More information online:
ilmt.co/PL/n23r 53450pr@reply-direct.com
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
